financetom
Business
financetom
/
Business
/
IPO-bound Delhivery buys rival firm Spoton to strengthen B2B logistics capabilities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IPO-bound Delhivery buys rival firm Spoton to strengthen B2B logistics capabilities
Aug 25, 2021 6:52 AM

Ahead of the IPO, homegrown logistics startup Delhivery is busy beefing up its business. The company on Tuesday announced the acquisition of its rival company Spoton for $200 million. This will give an exit as well as hefty returns to the Spoton investors - Samara capital and Xponential Fund Partners.

What does Spoton bring to the table for Delhivery?

The acquisition will enhance Delhivery's B2B express business capabilities. It will also provide synergistic benefits for the customers of the two delivery providers – Delhivery, as well as Spoton, with the B2B and B2C combination and, therefore, enhance the end-to-end supply chain capabilities.

Recently, Delhivery had collaborated with FedEx Express, which infused $100 million into the company and is also taking all these steps now to make the company more attractive for higher valuation in the IPO, which is underway.

The expected valuation of Delhivery by way of the IPO could be nearly $4 billion. The company is backed by marquee investors like Carlyle, SoftBank, and Tiger Global.

Delhivery had raised $275 million in May in a primary funding round led by Fidelity Management and Research Company. The funding took Delhivery's valuation to over $3 billion.

"This development is consistent with our objective of being growth-oriented and building scale in each of our business lines. Over 10 years, Delhivery has established a leading position in B2C logistics and now by combining our part truckload business with Spoton's we will be on the path to the same position in B2B express as well," Delhivery CEO Sahil Barua said.

Spoton Logistics managing director Abhik Mitra said the focus will continue to be on improving clients' businesses through investments in people, technology, network and infrastructure. "Our teams and our business partners will have an opportunity to be part of a much larger organisation with significant opportunities for growth," he said.

-With PTI inputs

For more, watch video

First Published:Aug 25, 2021 3:52 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
In race to regain rare earth glory, Europe falls short on mineral goals
In race to regain rare earth glory, Europe falls short on mineral goals
Jun 28, 2024
LONDON (Reuters) -Four decades ago, a rare earth processing plant on France's Atlantic coast was one of the largest in the world, churning out materials used to make colour televisions, arc lights and camera lenses. Its current owner Solvay is racing to return the plant at La Rochelle to its former glory after years of diminished output as Europe seeks...
Boeing woes will not erode workers' readiness to strike, union says
Boeing woes will not erode workers' readiness to strike, union says
Jun 28, 2024
SEATTLE (Reuters) -Boeing's financial and production challenges following a January mid-air panel blowout will not change its workers' readiness to strike to make gains in bargaining, a union local president said on Thursday. The International Association of Machinists and Aerospace Workers (IAM), which represents more than 30,000 Washington state workers building Boeing jets, wants better retirement benefits and wage increases...
EU regulator backs approval for ARS Pharma's nasal spray alternative to EpiPen
EU regulator backs approval for ARS Pharma's nasal spray alternative to EpiPen
Jun 28, 2024
June 28 (Reuters) - ARS Pharmaceuticals ( SPRY ) said on Friday the European Medicines Agency (EMA) has recommended the approval of its needle-free emergency treatment, EURneffy, for allergic reactions. The nasal spray EURneffy is seen as an alternative to EpiPen and other autoinjectors that are filled with epinephrine, a life-saving drug used by people at risk of anaphylaxis and...
INSIGHT-In race to regain rare earth glory, Europe falls short on mineral goals
INSIGHT-In race to regain rare earth glory, Europe falls short on mineral goals
Jun 28, 2024
(Adds comment from Swedish minister in paragraphs 30-31) By Eric Onstad LONDON, June 27 (Reuters) - Four decades ago, a rare earth processing plant on France's Atlantic coast was one of the largest in the world, churning out materials used to make colour televisions, arc lights and camera lenses. Its current owner Solvay is racing to return the plant at...
Copyright 2023-2026 - www.financetom.com All Rights Reserved